Logo

Intra-Cellular Reports the Expansion of Pipeline with the Addition of ITI-1284

Share this

Intra-Cellular Reports the Expansion of Pipeline with the Addition of ITI-1284

Shots:

  • Following the completion of a P-I program- the company plans to initiate P- II studies to evaluate ITI-1284 ODT-SL for the treatment of behavioral disturbances in dementia- dementia-related psychosis and certain depressive disorders in the elderly
  • The P-I single and multiple ascending dose studies in healthy volunteers including elderly subjects aged >65yrs. evaluated the safety- tolerability and PK of ITI-1284 and reported no SAEs in either age group
  • TI-1284 is a deuterated form of lumateperone- delivered sublingually as an ODT-SL and offer pharmacologic benefits and ease of use for patients- particularly in elderly populations

 ­ Ref: GlobeNewswire | Image: The Science of Parkinson's

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions